This research has led to the development of promising immunotherapies that target cells of the immune system to fight cancer, such as Immune Checkpoint Inhibition and CAR T cell therapies.
Immune Checkpoint Inhibitors have shown remarkable success for the treatment of advanced cancer, leading to unprecedented, long-lasting remission and potential cure in a fraction of patients.
Cancer cells have often developed mechanism to evade detection and destruction by the immune system in order to grow, which limits spontaneous anti-cancer immunity and the success of current immunotherapies. The group led by Dr. Jan Böttcher uses modern imaging techniques and bioinformatic analyses of cancer patient data to decipher the mechanisms that control anti-tumor immunity on a systemic level and locally within tumors and their surrounding microenvironment.
Major aims of the group are to identify and understand molecular mechanisms that could be targeted therapeutically to treat cancer, including the pathways that regulate the access of innate and adaptive immune cells into tumours, the initiation and modulation of immune cell phenotypes and the local communication between immune cells within tumor tissue.